The company says that Mohanty will be responsible for growing BioTime through development of subsidiaries and through further development and commercialization of the company’s HyStem product line.
“The addition of Adi to our senior management team is another execution milestone for BioTime as we broaden our capabilities to address market opportunities and build shareholder value,” said Dr. Michael West, BioTime’s Chief Executive Officer. “Adi is a highly experienced biopharmaceutical executive. He joins our Company at a time when two of our subsidiaries have been cleared for clinical trials of their therapeutic products and as we develop commercialization strategies for cancer diagnostics and Renevia™.
Mohanty most recently served as head of the Regenerative Medicine Business at Shire plc in San Diego. Prior to that, Mohanty was Shire’s global franchise head for a portfolio of biologic products in the rare disease space with sales and operations in over 50 countries. Mohanty holds BS and MS degrees in Chemical Engineering and an MBA.